Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol

Nature Communications

Volumn 6, Issue , 2015, Pages

  Hacke, Moritz ^a   Björkholm, Patrik ^b   Hellwig, Andrea ^a   Himmels, Patricia ^a   De Almodóvar, Carmen Ruiz ^a   Brügger, Britta ^a   Wieland, Felix ^a   Ernst, Andreas M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EBOLA VIRUS GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BETA CYCLODEXTRIN DERIVATIVE; CYTOCHALASIN B; HYPOCHOLESTEROLEMIC AGENT; METHYL-BETA-CYCLODEXTRIN; SIMVASTATIN; VIRULENCE FACTOR; VIRUS FUSION PROTEIN;

CELLS AND CELL COMPONENTS; INHIBITION; METABOLISM; MOLECULAR ANALYSIS; ORGANIC COMPOUND; PATHOGENICITY; PROTEIN; TOXICITY; VIRAL DISEASE; VIRUS;

ADHERENT CELL; ARTICLE; CYTOTOXICITY; EBOLAVIRUS; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; VIRUS ASSEMBLY; VIRUS ENVELOPE; ANIMAL; CELL ADHESION; CELL MEMBRANE; CHLOROCEBUS AETHIOPS; CONFOCAL MICROSCOPY; COS 1 CELL LINE; DRUG EFFECTS; FLOW CYTOMETRY; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; PATHOGENICITY; PROTEIN TERTIARY STRUCTURE; ULTRASTRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL;

EBOLA VIRUS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BETA-CYCLODEXTRINS; CELL ADHESION; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; CYTOCHALASIN B; EBOLAVIRUS; FLOW CYTOMETRY; HEK293 CELLS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICROSCOPY, CONFOCAL; PROTEIN STRUCTURE, TERTIARY; SIMVASTATIN; VIRAL FUSION PROTEINS; VIRULENCE FACTORS;

EID: 84937022260     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8688     Document Type: Article

References (67)

1. Check Hayden, E. World struggles to stop Ebola. Nature 512, 355-356 (2014).
2. Baize, S. et al. Emergence of Zaire Ebola Virus Disease in Guinea. N. Engl. J. Med. 371, 1418-1425 (2014).
3. Fedson, D. S. A practical treatment for patients with ebola virus disease. J. Infect. Dis. 211, 661-662 (2014).
4. McElroy, A. K. & Spiropoulou, C. F. Reply to Fedson. J. Infect. Dis. 211, 662-663 (2015).
5. Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849-862 (2011).
6. Yang, Z. Y. et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886-889 (2000).
7. Simmons, G., Wool-Lewis, R. J., Baribaud, F., Netter, R. C. & Bates, P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76, 2518-2528 (2002).
8. Geisbert, T. W. et al. Pathogenesis of ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 163, 2371-2382 (2003).
9. Wahl-Jensen, V. M. et al. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79, 10442-10450 (2005).
10. Francica, J. R., Matukonis, M. K. & Bates, P. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology 383, 237-247 (2009).
11. Groseth, A. et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 8, e1002847 (2012).
12. Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
13. Hunt, C. L., Lennemann, N. J. & Maury, W. Filovirus entry: a novelty in the viral fusion world. Viruses 4, 258-275 (2012).
14. Reynard, O. et al. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J. Virol. 83, 9596-9601 (2009).
15. Francica, J. R. et al. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog. 6, e1001098 (2010).
16. Hartlieb, B. & Weissenhorn, W. Filovirus assembly and budding. Virology 344, 64-70 (2006).
17. Jasenosky, L. D. & Kawaoka, Y. Filovirus budding. Virus Res. 106, 181-188 (2004).
18. Volchkov, V. E. et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291, 1965-1969 (2001).
19. Yang, Z. et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279, 1034-1037 (1998).
20. Wahl-Jensen, V. et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol. 79, 2413-2419 (2005).
21. de La Vega, M.-A., Wong, G., Kobinger, G. P. & Qiu, X. The multiple roles of sGP in ebola pathogenesis. Viral. Immunol. 28, 3-9 (2015).
22. Mohan, G. S., Li, W., Ye, L., Compans, R. W. & Yang, C. Antigenic subversion: a novel mechanism of host immune evasion by ebola virus. PLoS Pathog. 8, e1003065 (2012).
23. Escudero-Perez, B., Volchkova, V. A., Dolnik, O., Lawrence, P. & Volchkov, V. E. Shed GP of ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog. 10, e1004509 (2014).
24. Takada, A. et al. Downregulation of b1 integrins by ebola virus glycoprotein: implication for virus entry. Virology 278, 20-26 (2000).
25. Kuhl, A. et al. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204 (Suppl 3), S850-S860 (2011).
26. Volchkov, V. E., Feldmann, H., Volchkova, V. A. & Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. USA 95, 5762-5767 (1998).
27. Gallaher, W. R. Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses. Cell 85, 477-478 (1996).
28. Ito, H., Watanabe, S., Takada, A. & Kawaoka, Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75, 1576-1580 (2001).
29. Feldmann, H., Volchkov, V. E., Volchkova, V. A., Stroher, U. & Klenk, H. D. Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 82, 2839-2848 (2001).
30. Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605-616 (1998).
31. Sanchez, A. et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72, 6442-6447 (1998).
32. Chan, S. Y., Ma, M. C. & Goldsmith, M. A. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Gen. Virol. 81, 2155-2159 (2000).
33. Panchal, R. G. et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl Acad. Sci. USA 100, 15936-15941 (2003).
34. Timmins, J. et al. Oligomerization and polymerization of the filovirus matrix protein VP40. Virology 312, 359-368 (2003).
35. Timmins, J., Scianimanico, S., Schoehn, G. & Weissenhorn, W. Vesicular release of ebola virus matrix protein VP40. Virology 283, 1-6 (2001).
36. Noda, T. et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76, 4855-4865 (2002).
37. Licata, J. M., Johnson, R. F., Han, Z. & Harty, R. N. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78, 7344-7351 (2004).
38. Johnson, R. F., Bell, P. & Harty, R. N. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol. J. 3, 31 (2006).
39. Russ, W. P. & Engelman, D. M. The GxxxG motif: a framework for transmembrane helix-helix association. J. Mol. Biol. 296, 911-919 (2000).
40. Bavari, S. et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195, 593-602 (2002).
41. Colbeau, A., Nachbaur, J. & Vignais, P. M. Enzymic characterization and lipid composition of rat liver subcellular membranes. Biochim. Biophys. Acta 249, 462-492 (1971).
42. Eroglu, C., Brugger, B., Wieland, F. & Sinning, I. Glutamate-binding affinity of Drosophila metabotropic glutamate receptor is modulated by association with lipid rafts. Proc. Natl Acad. Sci. USA 100, 10219-10224 (2003).
43. Umashankar, M. et al. Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J. Virol. 82, 9245-9253 (2008).
44. Thiele, C., Hannah, M. J., Fahrenholz, F. & Huttner, W. B. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat. Cell Biol. 2, 42-49 (2000).
45. Anishkin, A. & Kung, C. Stiffened lipid platforms at molecular force foci. Proc. Natl Acad. Sci. USA 110, 4886-4892 (2013).
46. Rodal, S. K. et al. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 10, 961-974 (1999).
47. Negredo, A. et al. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. 7, e1002304 (2011).
48. Siegert, R., Shu, H.-L., Slenczka, W., Peters, D. & Müller, G. Zurätiologie einer unbekannten, von Affen ausgegangenen menschlichen Infektionskrankheit. Dtsch. Med. Wochenschr. 92, 2341-2343 (1967).
49. Ginsbach, C. & Fahimi, H. D. Labeling of cholesterol with filipin in cellular membranes of parenchymatous organs. Histochemistry 86, 241-248 (1987).
50. Anderson, H. A., Hiltbold, E. M. & Roche, P. A. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat. Immunol. 1, 156-162 (2000).
51. Janes, P. W., Ley, S. C., Magee, A. I. & Kabouridis, P. S. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin. Immunol. 12, 23-34 (2000).
52. Pinot, M. et al. Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science 345, 693-697 (2014).
53. Wong, G., Qiu, X., Olinger, G. G. & Kobinger, G. P. Post-exposure therapy of filovirus infections. Trends Microbiol. 22, 456-463 (2014).
54. Kilgore, P. E., Grabenstein, J. D., Salim, A. M. & Rybak, M. Treatment of ebola virus disease. Pharmacotherapy 35, 43-53 (2015).
55. Shurtleff, A. C., Whitehouse, C. A., Cazares, L. H., Ward, M. D. & Bavari, S. Pre-symptomatic diagnosis and treatment of filovirus diseases. Front. Microbiol. 6, 108 (2015).
56. Warren, T. K. et al. Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature 508, 402-405 (2014).
57. Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896-1905 (2010).
58. Johansen, L. M. et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5, 190ra179 (2013).
59. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
60. Thi, E. P. et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makonainfected nonhuman primates. Nature 521, 362-365 (2015).
61. Carlson, R. M., Froberg, M. K., Khan, M. A., Rice, S. A. & Wallace, K. B. Cyclodextrin compositions and methods of treating viral infections. Patent WO 2003080080 A1 (2003).
62. Adu-Gyamfi, E. et al. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J. Biol. Chem. 288, 5779-5789 (2013).
63. UniProt Consortium. Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res. 41, D43-D47 (2013).
64. Huang, Y., Niu, B., Gao, Y., Fu, L. & Li, W. CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics 26, 680-682 (2010).
65. Hessa, T. et al. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature 450, 1026-1030 (2007).
66. Contreras, F. X. et al. Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. Nature 481, 525-529 (2012).
67. Chou, K. C., Zhang, C. T. & Maggiora, G. M. Disposition of amphiphilic helices in heteropolar environments. Proteins 28, 99-108 (1997).